Cytosorbents Reveals 2026 Cash Flow Break-Even Plan as Global Sales Rise

Earnings Call Insights: Cytosorbents Corporation (CTSO) Q4 2025

During the recent earnings call, Cytosorbents Corporation provided an overview of its performance in 2025 and outlined key priorities for the future. The company’s CEO, Phillip Chan, described 2025 as a transitional year marked by progress across four main areas: driving sales growth outside of Germany, advancing DrugSorb-ATR through the FDA process, restructuring operations in Germany, and focusing on long-term success.

Management View

The CEO highlighted that full-year 2025 sales revenues increased by 4% to $37.1 million, which represents record core product sales. Direct sales outside of Germany rose by 13%, while distributor sales increased by 11.4%. However, German sales declined by 10% to $11.8 million, attributed to the ongoing restructuring efforts. Despite this, there were early signs of improvement in the first quarter of 2026 in Germany.

Cytosorbents also announced the launch of the PuriFi hemoperfusion pump and the HotSwap cartridge exchange system. These new products aim to expand access in regions with limited dialysis infrastructure. The PuriFi pump is positioned as a strategic move to increase unit volume and drive disposables like CytoSorb.

Regarding DrugSorb-ATR, the CEO noted that the initial De Novo submission was denied, but the appeal outcome provided two critical positives. There were no concerns regarding device safety, and the FDA aligned on focusing the next submission on the remaining open items.

The CFO, Peter Mariani, reported that full-year 2025 revenue reached $37.1 million, up 4% compared to the previous year. On a constant currency basis, revenue remained flat. Gross margin improved to 71% for the year, compared to 70% in 2024. Operating loss for 2025 improved by 10% to $14.7 million from $16.5 million in 2024.

Outlook

The company remains focused on consistent revenue growth, executing the Germany turnaround, advancing DrugSorb-ATR towards FDA market authorization, and achieving cash flow breakeven. The CFO indicated that operating cash burn is expected to decrease as working capital dynamics normalize over the first half of the year. The company now expects to be operating cash flow breakeven in the second half of 2026.

Management emphasized the goal of returning Germany to growth and leveraging innovations like PuriFi and HotSwap for future revenue expansion.

Financial Results

For Q4 2025, revenue was $9.2 million, an increase of 1% year-over-year but down 8% on a constant currency basis compared to the same period last year. Gross margin for Q4 2025 improved to 74%, up from 71% in Q4 2024.

Operating expenses for the quarter were $11.4 million, including a $500,000 restructuring charge. Operating loss in Q4 was $4.6 million, and net loss improved to $5.5 million for the quarter or $0.09 per share, compared to a net loss of $7.6 million or $0.14 per share in the prior year.

Adjusted net loss for the quarter was $4.3 million or $0.07 per share. Cash, cash equivalents, and restricted cash totaled $7.8 million as of December 31.

Q&A

During the Q&A session, analysts raised several questions about regulatory timelines, Germany’s restructuring, and financial discipline. The CEO reiterated that the company continues to have interactive discussions with the FDA and will provide updates when visibility improves.

On the topic of Germany’s restructuring, the CEO confirmed that the plan is in place and the focus is now on execution. The CFO mentioned that the company aims to maintain gross margins in the range of 71% to 74%.

Regarding the PuriFi pump, the CEO compared it to the “printer cartridge business,” emphasizing the potential for increased unit volume in disposables. The CFO also discussed cost management, noting that headcount reductions in Q4 are helping to reduce spending and move closer to breakeven.

Sentiment Analysis

Analysts maintained a neutral tone, focusing on regulatory timelines, Germany’s restructuring, and cost management. There was persistent interest in execution milestones and financial discipline.

Management displayed a cautiously optimistic tone, emphasizing progress while acknowledging ongoing challenges. Phrases such as “we believe…” and “we are encouraged…” reflected careful optimism without overconfidence.

Compared to the previous quarter, both analysts and management maintained a pragmatic and methodical sentiment. The tone remained consistent, with no significant shift in confidence levels, though management provided more concrete updates on Germany and breakeven targets.

Quarter-over-Quarter Comparison

Guidance language shifted from targeting cash flow breakeven in Q1 2026 to the second half of 2026, reflecting a more measured outlook on operational improvements. Strategic focus expanded with the launch of the PuriFi pump and HotSwap system, while the German market turnaround remained central.

Analysts continued to focus on regulatory progress, gross margins, and restructuring execution. Key metrics reflected modest revenue growth and improved gross margins, but also highlighted persistent losses and ongoing restructuring costs.

Management’s confidence in the restructuring process and product pipeline remained steady, with more explicit discussion of progress in Germany and FDA engagement.

Risks and Concerns

Management cited continued execution challenges in Germany and the need to align the cost structure to support a path to cash flow breakeven. Regulatory uncertainty around DrugSorb-ATR persists, with the CEO noting ongoing discussions with the FDA and the need to avoid another denial.

Analysts expressed concern about the pace of operational improvements and the timeline for achieving breakeven.

Final Takeaway

Cytosorbents’ management reiterated a focus on returning Germany to growth, advancing DrugSorb-ATR’s regulatory approval, and achieving cash flow breakeven in the second half of 2026. The company reported record product sales, incremental improvements from new product launches, and continued cost controls, while acknowledging ongoing challenges in Germany and the U.S. regulatory process. Management positioned these strategic initiatives as key to creating long-term value.